Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc.CRVS · Entity 4839 | Director | June 09, 2020 | June 12, 2020 |
| Denali Therapeutics Inc.DNLI · Entity 1735 | Director | June 03, 2026 | June 05, 2026 |
| Gritstone bio, Inc.GRTS · Entity 80946 | Director | June 16, 2023 | June 21, 2023 |
| Guardant Health, Inc.GH · Entity 3238 | Director | September 16, 2026 | September 17, 2026 |
| PLIANT THERAPEUTICS, INC.PLRX · Entity 7022 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Corvus Pharmaceuticals, Inc.
Report date June 09, 2020 · Filed June 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.27 · Expires 2030-06-09 | Direct | 15,000 |
Reported balance
After 2020-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-09 · Grant · Acquired 15,000 · Balance 15,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
Denali Therapeutics Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,202 |
Reported balance
After 2026-06-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 6,408 · Balance 38,202 F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2: Includes 6,408 unvested RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.66 · Expires 2036-06-03 | Direct | 19,226 |
Reported balance
After 2026-06-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-03 · Grant · Acquired 19,226 · Balance 19,226 F4: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 781,797 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 781,797 F3: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
F2: Includes 6,408 unvested RSUs.
F3: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee.
F4: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
Gritstone bio, Inc.
Report date June 16, 2023 · Filed June 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.19 · Expires 2033-06-15 | Direct | 51,800 |
Reported balance
After 2023-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-16 · Grant · Acquired 51,800 · Balance 51,800 F1: The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date.
Guardant Health, Inc.
Report date September 16, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,906 |
Ending reported balance
After 2026-09-16 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-09-16 · Sale · Disposed 1,103 · Balance 13,477 F1: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $173.98 to $174.975. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Row 2 · 2026-09-16 · Sale · Disposed 3,300 · Balance 10,177 F2: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $175.02 to $176.01. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Row 3 · 2026-09-16 · Sale · Disposed 1,300 · Balance 8,877 F3: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $176.055 to $176.88. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Row 4 · 2026-09-16 · Sale · Disposed 971 · Balance 7,906 F4: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $177.08 to $177.945. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $173.98 to $174.975. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F2: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $175.02 to $176.01. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $176.055 to $176.88. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $177.08 to $177.945. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
PLIANT THERAPEUTICS, INC.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.14 · Expires 2036-06-11 | Direct | 70,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 70,000 · Balance 70,000 F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2026 Filed Sep 17, 2026 21:10 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 971 | $177.48 | $172,329.78 |
DisclosureSEC source: 0001666236-26-000024 · wk-form4_1789679434.xml · nonDerivative · entry 4 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,906 F4 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $177.08 to $177.945. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 16, 2026 Filed Sep 17, 2026 21:10 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 1,300 | $176.34 | $229,236.02 |
DisclosureSEC source: 0001666236-26-000024 · wk-form4_1789679434.xml · nonDerivative · entry 3 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,877 F3 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $176.055 to $176.88. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 16, 2026 Filed Sep 17, 2026 21:10 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 3,300 | $175.42 | $578,887.98 |
DisclosureSEC source: 0001666236-26-000024 · wk-form4_1789679434.xml · nonDerivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,177 F2 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $175.02 to $176.01. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 16, 2026 Filed Sep 17, 2026 21:10 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 1,103 | $174.46 | $192,431.92 |
DisclosureSEC source: 0001666236-26-000024 · wk-form4_1789679434.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,477 F1 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $173.98 to $174.975. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 22:07 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 155 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001666236-26-000022 · wk-form4_1783030048.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 155 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022. 25% of the shares subject to such award vested on June 30, 2023 and the remaining 75% of the shares subject to such award vested during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 22:07 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 155 | $0.00 | $0.00 |
DisclosureSEC source: 0001666236-26-000022 · wk-form4_1783030048.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:53 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantRestricted Stock Units · Derivative | 2,711 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001666236-26-000020 · wk-form4_1782165212.xml · derivative · entry 3 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,711 Underlying: Common Stock · 2,711 shares Expires not disclosed F3 · derivative.exercise_date: The restricted stock unit award vests in full on the one-year anniversary of the grant date, June 17, 2026, or the date of the Company's next annual meeting of stockholders, whichever is earlier. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:53 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 4,203 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001666236-26-000020 · wk-form4_1782165212.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,203 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit award vested in full on the date of the 2026 Annual Meeting of Stockholders which was held on June 17, 2026. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:53 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 4,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001666236-26-000020 · wk-form4_1782165212.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 21:01 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001746473-26-000102 · wk-form4_1781298070.xml · derivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 23:50 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 9,294 | $132.51 | $1,231,521.92 |
DisclosureSEC source: 0001666236-26-000018 · wk-form4_1780703425.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,222 F1 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.50 to $132.71. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:45 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 19,226 | $0.00 Strike: $19.66 | $0.00 |
DisclosureSEC source: 0001666236-26-000015 · wk-form4_1780692340.xml · derivative · entry 3 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,226 Underlying: Common Stock · 19,226 shares Expires 2036-06-03 F4 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:45 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 6,408 | $0.00 | $0.00 |
DisclosureSEC source: 0001666236-26-000015 · wk-form4_1780692340.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,202 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 6,408 unvested RSUs. Read SEC document |
| May 31, 2026 Filed Jun 1, 2026 21:30 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001666236-26-000013 · wk-form4_1780349455.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155 Underlying: Common Stock · 154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vested 25% of the shares subject to such award on June 30, 2023. The remaining 75% of the shares subject to such award vests in substantially equal installments each month during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| May 31, 2026 Filed Jun 1, 2026 21:30 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001666236-26-000013 · wk-form4_1780349455.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2026 Filed May 1, 2026 21:45 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001666236-26-000011 · wk-form4_1777671928.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 309 Underlying: Common Stock · 154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022. 25% of the shares subject to such award vested on June 30, 2023 and as to the remaining 75% of the shares subject to such award vests in substantially equal installments each month during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| April 30, 2026 Filed May 1, 2026 21:45 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001666236-26-000011 · wk-form4_1777671928.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,362 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:31 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 155 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001666236-26-000009 · wk-form4_1775079068.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 463 Underlying: Common Stock · 155 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vests over 4 years. 25% of the shares subject to such award vested on June 30, 2023 and the remaining 75% of the shares subject to such award vests in substantially equal monthly installments during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:31 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 155 | $0.00 | $0.00 |
DisclosureSEC source: 0001666236-26-000009 · wk-form4_1775079068.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2026 Filed Mar 2, 2026 21:24 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001666236-26-000006 · wk-form4_1772486659.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 618 Underlying: Common Stock · 154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vested as to 25% of the shares subject to such award on June 30, 2023. The remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of June 30, 2023 during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| February 28, 2026 Filed Mar 2, 2026 21:24 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001666236-26-000006 · wk-form4_1772486659.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2026 Filed Feb 2, 2026 21:30 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001666236-26-000004 · wk-form4_1770067824.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 772 Underlying: Common Stock · 154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vested as to 25% of the shares subject to such award on June 30, 2023. The remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| January 31, 2026 Filed Feb 2, 2026 21:30 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001666236-26-000004 · wk-form4_1770067824.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,899 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 22:54 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001666236-26-000002 · wk-form4_1767653696.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 926 Underlying: Common Stock · 154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vested 25% of the shares subject to such award on June 30, 2023. The remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 22:54 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001666236-26-000002 · wk-form4_1767653696.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2025 Filed Dec 2, 2025 02:41 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 155 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001666236-25-000013 · wk-form4_1764643300.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,080 Underlying: Common Stock · 155 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vested as to 25% of the shares subject to such award on June 30, 2023. The remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of June 30, 2023, during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| November 30, 2025 Filed Dec 2, 2025 02:41 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 155 | $0.00 | $0.00 |
DisclosureSEC source: 0001666236-25-000013 · wk-form4_1764643300.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2025 Filed Nov 3, 2025 22:45 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001666236-25-000011 · wk-form4_1762209933.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,235 Underlying: Common Stock · 154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vested as to 25% of the shares subject to such award on June 30, 2023. The remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of June 30, 2023 during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| October 31, 2025 Filed Nov 3, 2025 22:45 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001666236-25-000011 · wk-form4_1762209933.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2025 Filed Oct 3, 2025 00:03 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001666236-25-000009 · wk-form4_1759449808.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,389 Underlying: Common Stock · 154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vested as to 25% of the shares subject to such award on June 30, 2023. The remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of June 30, 2023 during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| September 30, 2025 Filed Oct 3, 2025 00:03 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001666236-25-000009 · wk-form4_1759449808.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2025 Filed Sep 3, 2025 22:43 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 155 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001666236-25-000007 · wk-form4_1756939377.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,543 Underlying: Common Stock · 155 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vested 25% of the shares subject to such award on June 30, 2023. The remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of June 30, 2023 during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| August 31, 2025 Filed Sep 3, 2025 22:43 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 155 | $0.00 | $0.00 |
DisclosureSEC source: 0001666236-25-000007 · wk-form4_1756939377.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2025 Filed Aug 4, 2025 23:13 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000248 · wk-form4_1754349234.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,698 Underlying: Common Stock · 154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vested 25% of the shares subject to such award `on June 30, 2023. The remaining 75% of the shares subject to such award vest in substantially equal installments on each monthly anniversary of June 30, 2023 during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| July 31, 2025 Filed Aug 4, 2025 23:13 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000248 · wk-form4_1754349234.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2025 Filed Jul 3, 2025 01:17 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000211 · wk-form4_1751505444.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,852 Underlying: Common Stock · 154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vested 25% of the shares subject to such award on June 30, 2023. The remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of June 30, 2023 during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| June 30, 2025 Filed Jul 3, 2025 01:17 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000211 · wk-form4_1751505444.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,819 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 21:37 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantRestricted Stock Units · Derivative | 4,203 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000201 · wk-form4_1750455454.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,203 Underlying: Common Stock · 4,203 shares Expires not disclosed F2 · derivative.exercise_date: The restricted stock units vest in full on the one-year anniversary of the grant date, June 18, 2025 or the date of the next year annual stockholders meeting, whichever is earlier. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 21:37 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantStock Option (Right to Buy) · Derivative | 6,833 | $0.00 Strike: $50.57 | $0.00 |
DisclosureSEC source: 0001576280-25-000201 · wk-form4_1750455454.xml · derivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,833 Underlying: Common Stock · 6,833 shares Expires 2035-06-18 F1 · derivative.exercise_date: The stock option vests in full on the one-year anniversary of the grant date, June 18, 2025 or the date of the next year annual stockholders meeting, whichever is earlier. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 23:24 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 6,674 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000175 · wk-form4_1750116269.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,674 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in full on the one-year anniversary of the grant date, June 12, 2024 or the date of the next year annual stockholders meeting, whichever is earlier. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 23:24 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 6,674 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000175 · wk-form4_1750116269.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2025 Filed Jun 10, 2025 00:43 UTC | PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 | GrantCommon Stock (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001746473-25-000128 · wk-form4_1749516225.xml · derivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-06-05 F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 20:29 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 18,111 | $0.00 Strike: $13.93 | $0.00 |
DisclosureSEC source: 0001714899-25-000139 · wk-form4_1749155311.xml · derivative · entry 3 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,111 Underlying: Common Stock · 18,111 shares Expires 2035-06-03 F4 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 20:29 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 6,037 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-25-000139 · wk-form4_1749155311.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,794 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 6,037 unvested RSUs. Read SEC document |
| May 31, 2025 Filed Jun 2, 2025 22:01 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000155 · wk-form4_1748901697.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,006 Underlying: Common Stock · 154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vested 25% of the shares subject to such award on June 30, 2023. The remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of June 30, 2023 during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| May 31, 2025 Filed Jun 2, 2025 22:01 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000155 · wk-form4_1748901697.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2025 Filed May 1, 2025 20:56 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 155 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000138 · wk-form4_1746132996.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,160 Underlying: Common Stock · 155 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vested 25% of the shares subject to such award on June 30, 2023. The remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of June 30, 2023 during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| April 30, 2025 Filed May 1, 2025 20:56 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 155 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000138 · wk-form4_1746132996.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:27 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 154 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000108 · wk-form4_1743629267.xml · derivative · entry 2 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,315 Underlying: Common Stock · 154 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This represents a restricted stock unit award granted on August 9, 2022 that vested 25% of the shares subject to such award on June 30, 2023. The remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of June 30, 2023 during the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:27 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 154 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000108 · wk-form4_1743629267.xml · nonDerivative · entry 1 Krognes Steve E. · CIK 0001666236 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.